149 related articles for article (PubMed ID: 17488193)
1. Toll-like receptor 9 ligand blocks osteoclast differentiation through induction of phosphatase.
Amcheslavsky A; Bar-Shavit Z
J Bone Miner Res; 2007 Aug; 22(8):1301-10. PubMed ID: 17488193
[TBL] [Abstract][Full Text] [Related]
2. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides.
Amcheslavsky A; Bar-Shavit Z
J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377
[TBL] [Abstract][Full Text] [Related]
3. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis.
Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z
J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640
[TBL] [Abstract][Full Text] [Related]
4. CpG oligonucleotides: novel regulators of osteoclast differentiation.
Zou W; Schwartz H; Endres S; Hartmann G; Bar-Shavit Z
FASEB J; 2002 Mar; 16(3):274-82. PubMed ID: 11874977
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 9 regulates tumor necrosis factor-alpha expression by different mechanisms. Implications for osteoclastogenesis.
Amcheslavsky A; Zou W; Bar-Shavit Z
J Biol Chem; 2004 Dec; 279(52):54039-45. PubMed ID: 15485822
[TBL] [Abstract][Full Text] [Related]
6. CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via Toll-like receptor 9.
Zou W; Amcheslavsky A; Bar-Shavit Z
J Biol Chem; 2003 May; 278(19):16732-40. PubMed ID: 12611893
[TBL] [Abstract][Full Text] [Related]
7. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
8. Cytidine-phosphate-guanosine oligonucleotides induce interleukin-8 production through activation of TLR9, MyD88, NF-κB, and ERK pathways in odontoblast cells.
He W; Zhang Y; Zhang J; Yu Q; Wang P; Wang Z; Smith AJ
J Endod; 2012 Jun; 38(6):780-5. PubMed ID: 22595112
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
10. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
11. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells.
Mozar A; Haren N; Chasseraud M; Louvet L; Mazière C; Wattel A; Mentaverri R; Morlière P; Kamel S; Brazier M; Mazière JC; Massy ZA
J Cell Physiol; 2008 Apr; 215(1):47-54. PubMed ID: 17894387
[TBL] [Abstract][Full Text] [Related]
12. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
[TBL] [Abstract][Full Text] [Related]
13. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of osteoclast differentiation induced by IL-1.
Kim JH; Jin HM; Kim K; Song I; Youn BU; Matsuo K; Kim N
J Immunol; 2009 Aug; 183(3):1862-70. PubMed ID: 19587010
[TBL] [Abstract][Full Text] [Related]
16. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
17. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH
Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
20. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]